Biogen reported that its oral MS drug, BG-12 (dimethyl fumarate), performed well in its latest pivotal trial and met its goal in reducing MS flare-ups over two years. The drug also met secondary goals of reducing the number of new or enlargin brain lesions and slowing the rate of disability.
BG-12 is on the cusp of joining Biogen's other MS stable-mates, Avonex (interferon B) and Tysabri (natalizumab), to stregthen its industry leading MS franchise. In addition to the benefits cited above, BG-12 was also said to offer a good safety profile and the convenience of taking it orally is considered big plus to patients. Biogen shares were up 5% on the news. See Xconomy.
Posted by Bruce Lehr April 11th 2011.